 "Dishman buys partner's 50% stake in JV Schutz Dishman")
Dishman Pharmaceuticals and Chemicals Ltd has acquired further 50 percent stake in Schutz Dishman Biotech Ltd, a joint venture Indian company, from the existing partner, Schutz & Co Beteiligungsgesellschaft MBH of Germany, for a consideration of Euro 300,000 (about Rs 2.26 crore). Dishman currently holds 22.33 percent stake in Schutz Dishman and after acquisition of further 50 percent stake, Schutz Dishman will become subsidiary of the company.
Schutz Dishman Biotech Ltd (Schutz Dishman) is engaged in the business of manufacturing of bulk drugs, drug formulations and performance chemicals in India for export markets. Its plant is USFDA approved and is located in the existing campus of Dishman’s Bavla manufacturing facility, near Ahmedabad (Gujarat).
The acquisition of additional 50 percent stake in the JV will help Dishman in backward integration for some of its existing products and for manufacturing other APIs.
Schutz Dishman Biotech Ltd (Schutz Dishman) is engaged in the business of manufacturing of bulk drugs, drug formulations and performance chemicals in India for export markets. Its plant is USFDA approved and is located in the existing campus of Dishman’s Bavla manufacturing facility, near Ahmedabad (Gujarat).
The acquisition of additional 50 percent stake in the JV will help Dishman in backward integration for some of its existing products and for manufacturing other APIs.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%